Eliquis Tied to Less Bleeding in Afib Versus Other NOACs

ACC Conference Reporter

ESC 2015 | LONDON — In a comparison of bleeding risks among non-valvular atrial fibrillation patients being treated for stroke prevention, those on apixaban (Eliquis) appeared to do better than those on dabigatran (Pradaxa) and rivaroxaban (Xarelto) with regard to bleeding, researchers reported here. Read More >>>

Keywords: ESC Congress

< Back to Listings